Alpha Tau Medical (NASDAQ: DRTS) CEO details equity holdings

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. director and CEO Uzi Sofer has filed an initial statement of holdings. He reports direct ownership of 1,250,941 Ordinary Shares, plus 4,680 Restricted Share Units that will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting, subject to continued service.

Sofer also holds a large portfolio of stock options over Ordinary Shares at exercise prices ranging from $1.10 to $11.50, with expirations between 2027 and 2036. According to the footnotes, some of these options are already fully vested, while others vest either in full on a one-year schedule tied to March 9, 2026 and the next Annual General Meeting, or in equal quarterly installments over four years starting January 1, 2026, all contingent on his continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sofer Uzi

(Last) (First) (Middle)

C/O ALPHA TAU MEDICAL LTD.

(Street)

JERUSALEM 9777605

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,250,941	D
Restricted Share Units(1)	4,680	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options(2)	01/01/2017	02/21/2027	Ordinary Shares	54,318	$1.1	D
Options(2)	03/01/2019	11/26/2028	Ordinary Shares	54,318	$4.42	D
Options(2)	06/07/2022	08/08/2031	Ordinary Shares	174,770	$11.5	D
Options(2)	11/02/2022	03/21/2032	Ordinary Shares	8,945	$10.92	D
Options(2)	06/07/2022	03/21/2032	Ordinary Shares	229,089	$10.92	D
Options(2)	11/02/2022	06/02/2032	Ordinary Shares	10,657	$7.19	D
Options(2)	06/07/2022	06/02/2032	Ordinary Shares	250,933	$7.19	D
Options(2)	01/01/2024	03/09/2033	Ordinary Shares	46,905	$3.28	D
Options(2)	04/01/2023	03/09/2033	Ordinary Shares	1,102,653	$3.57	D
Options(2)	12/17/2024	03/07/2034	Ordinary Shares	43,257	$2.98	D
Options(2)	04/01/2024	03/07/2034	Ordinary Shares	763,843	$3.48	D
Options(2)	06/17/2025	01/22/2035	Ordinary Shares	24,460	$4.05	D
Options(2)	04/01/2025	01/22/2035	Ordinary Shares	674,238	$3.07	D
Options(3)	(3)	03/09/2036	Ordinary Shares	15,527	$6.41	D
Options(4)	(4)	03/09/2036	Ordinary Shares	396,680	$7.32	D

Explanation of Responses:

1. These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

2. These are options to acquire ordinary shares, which have fully vested as of the date hereof.

3. These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

4. These are options to acquire ordinary shares, which options which vest in quarterly equal installments for a period of four years commencing January 1, 2026, subject to the Reporting Person's continued service.

	/s/ Uzi Sofer	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Alpha Tau Medical (DRTS) CEO Uzi Sofer report in this Form 3 filing?

Uzi Sofer reports his initial equity holdings in Alpha Tau Medical. He directly holds 1,250,941 Ordinary Shares, 4,680 Restricted Share Units, and multiple stock option grants over Ordinary Shares with various exercise prices and maturities extending out to 2036, all as of this filing.

How many Alpha Tau Medical (DRTS) Ordinary Shares does Uzi Sofer directly own?

Uzi Sofer reports direct ownership of 1,250,941 Ordinary Shares. This figure represents his common equity position separate from options and restricted units. It provides a clear view of his existing share stake before any future option exercises or RSU vesting events occur.

What Restricted Share Units does the Alpha Tau Medical (DRTS) CEO hold and when do they vest?

The CEO holds 4,680 Restricted Share Units in Alpha Tau Medical. These RSUs vest in their entirety upon the earlier of one year commencing from March 9, 2026 or the next Annual General Meeting, provided he continues serving the company through the applicable vesting date.

What stock option grants over Alpha Tau Medical (DRTS) shares are disclosed in this Form 3?

The filing lists multiple option grants over Ordinary Shares with exercise prices from $1.10 to $11.50 and expirations from 2027 to 2036. Some option series are fully vested, while others follow time-based vesting schedules tied to March 9, 2026 and January 1, 2026 dates.

Are Uzi Sofer’s Alpha Tau Medical (DRTS) options already vested or still vesting?

The filing explains that certain option grants are fully vested as of the filing date. Other grants will vest either entirely after one year from March 9, 2026 or in equal quarterly installments over four years from January 1, 2026, all subject to continued service.

Does this Alpha Tau Medical (DRTS) Form 3 show any insider buying or selling activity?

No buy or sell transactions are reported in this Form 3. The entries are classified as holdings, meaning the document simply discloses Uzi Sofer’s existing Ordinary Shares, Restricted Share Units, and outstanding stock options without recording new market trades.